Pang, Wei
Lu, Ying
Zhao, Yan-Bo
Shen, Fan
Fan, Chang-Fa
Wang, Qian
He, Wen-Qiang
He, Xiao-Yan
Li, Ze-Kai
Chen, Tao-Tao
Yang, Cui-Xian
Li, You-Zhi
Xiao, Si-Xuan
Zhao, Zu-Jiang
Huang, Xu-Sheng
Luo, Rong-Hua
Yang, Liu-Meng
Zhang, Mi
Dong, Xing-Qi
Li, Ming-Hua
Feng, Xiao-Li
Zhou, Qing-Cui
Qu, Wang
Jiang, Shibo http://orcid.org/0000-0001-8283-7135
Ouyang, Songying http://orcid.org/0000-0002-1120-1524
Zheng, Yong-Tang http://orcid.org/0000-0001-5469-0324
Funding for this research was provided by:
National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (U1802284)
National Natural Science Foundation of China (82071847, 81971548, 82151218, 92169112, 82172287)
Article History
Received: 27 July 2022
Accepted: 27 October 2022
First Online: 10 November 2022
Competing interests
: Y.T.Z., W.P., Y.L., W.Q.H., X.Y.H., R.H.L., and F.S. are listed as inventors on the Chinese patent of “A recombinant fusion protein derived from HR domains in S2 subunit of SARS-CoV-2 and its application (authorization No.: ZL202111167024.2)” related to this work. The other authors declare no competing interests.